Bollini Mariela, Leal Emilse S, Adler Natalia S, Aucar María G, Fernández Gabriela A, Pascual María J, Merwaiss Fernando, Alvarez Diego E, Cavasotto Claudio N
Laboratorio de Química Medicinal, Centro de Investigaciones en Bionanociencias, Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad de Buenos Aires, Argentina.
Laboratory of Computational Chemistry and Drug Design, Instituto de Investigación en Biomedicina de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Partner Institute of the Max Planck Society, Ciudad de Buenos Aires, Argentina.
Front Chem. 2018 Mar 26;6:79. doi: 10.3389/fchem.2018.00079. eCollection 2018.
Bovine viral diarrhea virus (BVDV) is a member of the genus Pestivirus within the family Flaviviridae. BVDV causes both acute and persistent infections in cattle, leading to substantial financial losses to the livestock industry each year. The global prevalence of persistent BVDV infection and the lack of a highly effective antiviral therapy have spurred intensive efforts to discover and develop novel anti-BVDV therapies in the pharmaceutical industry. Antiviral targeting of virus envelope proteins is an effective strategy for therapeutic intervention of viral infections. We performed prospective small-molecule high-throughput docking to identify molecules that likely bind to the region delimited by domains I and II of the envelope protein E2 of BVDV. Several structurally different compounds were purchased or synthesized, and assayed for antiviral activity against BVDV. Five of the selected compounds were active displaying IC values in the low- to mid-micromolar range. For these compounds, their possible binding determinants were characterized by molecular dynamics simulations. A common pattern of interactions between active molecules and aminoacid residues in the binding site in E2 was observed. These findings could offer a better understanding of the interaction of BVDV E2 with these inhibitors, as well as benefit the discovery of novel and more potent BVDV antivirals.
牛病毒性腹泻病毒(BVDV)是黄病毒科瘟病毒属的成员。BVDV可引起牛的急性和持续性感染,每年给畜牧业造成重大经济损失。持续性BVDV感染在全球的流行以及缺乏高效的抗病毒疗法,促使制药行业大力开展发现和开发新型抗BVDV疗法的工作。针对病毒包膜蛋白进行抗病毒治疗是治疗病毒感染的有效策略。我们进行了前瞻性小分子高通量对接,以鉴定可能与BVDV包膜蛋白E2的结构域I和II界定的区域结合的分子。购买或合成了几种结构不同的化合物,并检测其对BVDV的抗病毒活性。所选的5种化合物具有活性,其半数抑制浓度(IC)值在低至中微摩尔范围内。对于这些化合物,通过分子动力学模拟对其可能的结合决定因素进行了表征。观察到活性分子与E2结合位点中的氨基酸残基之间存在共同的相互作用模式。这些发现有助于更好地理解BVDV E2与这些抑制剂的相互作用,也有利于发现新型、更有效的BVDV抗病毒药物。